FiercePharma | For Pharmaceuticals Industry Pros
0 FOLLOWERS
Follow FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and other pharma news.
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
AbbVie's red-hot Rinvoq scores fourth FDA approval in five months kdunleavy Fri, 04/29/2022 - 16:40 ..read more
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
Pfizer loses top vaccine scientist Jansen who led drive for COVID-19 shot, searches for successor esagonowsky Fri, 04/29/2022 - 15:23 ..read more
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
The Top Line podcast: Pharma advertising shifts gears and Novartis taps a surprising M&A czar, plus this week's headlines tcarey Thu, 04/28/2022 - 20:30 ..read more
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
Novo's Wegovy supply rebound on track for later this year as demand stays strong fkansteiner Fri, 04/29/2022 - 13:32 ..read more
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
Amid legal tumult, J&J shareholders reject proposal to end talc sales worldwide kdunleavy Fri, 04/29/2022 - 13:04 ..read more
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
Ahead of Humira patent cliff, AbbVie's Rinvoq comes up short of analyst forecasts while Skyrizi delivers zbecker Fri, 04/29/2022 - 11:05 ..read more
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
AstraZeneca’s Farxiga hits $1B quarterly mark, but flagship oncology and China units lag aliu Fri, 04/29/2022 - 10:46 ..read more
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
As superstar Revlimid fades faster than expected, BMS trims $600M from its 2022 sales projection kdunleavy Fri, 04/29/2022 - 10:02 ..read more
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
Fierce Pharma Asia—Astellas’ gene therapy write-off; BeiGene, Novartis’ PD-1 win; Serum Institute’s unused COVID shots aliu Fri, 04/29/2022 - 08:53 ..read more
FiercePharma | For Pharmaceuticals Industry Pros
2y ago
Gilead's two cents: Drugmaker gets a boost from Biktarvy, Veklury but $2.7B writedown crushes earnings zbecker Fri, 04/29/2022 - 08:03 ..read more